Dr. Yair Lotan, MD
What this data tells you about Dr. Lotan
Dr. Yair Lotan is an urology physician in Dallas, TX, with 20 years in practice. Based on federal Medicare data, Dr. Lotan performed 7,276 Medicare services across 1,549 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lotan received a total of $340,776 from 51 pharmaceutical and/or device companies across 286 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lotan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| BCG treatment for bladder cancer | 2,831 | $2 | $10 |
| Injection, docetaxel, 1 mg | 1,800 | $0 | $4 |
| Office visit, established patient (30-39 min) | 711 | $91 | $344 |
| Diagnostic exam of bladder and urethra using an endoscope | 450 | $178 | $837 |
| Urinalysis, manual | 340 | $3 | $18 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 296 | $3 | $395 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 144 | $135 | $2,030 |
| Instillation of anti-cancer drug into bladder | 112 | $67 | $468 |
| Office visit, established patient (20-29 min) | 101 | $62 | $232 |
| Instillation, hexaminolevulinate hydrochloride, 100 mg | 69 | $962 | $4,405 |
| Office visit, established patient, complex (40-54 min) | 57 | $134 | $464 |
| New patient office visit, complex (60-74 min) | 55 | $151 | $664 |
| New patient office visit (45-59 min) | 54 | $110 | $533 |
| Bladder ultrasound after voiding | 38 | $8 | $80 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $53 | $138 |
| Hospital follow-up visit, moderate complexity | 29 | $61 | $234 |
| Insertion of stent in ureter using an endoscope | 25 | $109 | $2,442 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $25 | $143 |
| Office visit, established patient (10-19 min) | 24 | $41 | $140 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 23 | $199 | $1,356 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 18 | $605 | $3,724 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $76 | $212 |
| Electronic assessment of bladder emptying | 15 | $10 | $340 |
| Simple bladder irrigation and/or instillation | 12 | $58 | $346 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (94%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 1% for urology physician in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Lotan is a mixed practice specialist, with above-average Medicare volume (top 14% in TX), and high industry engagement (consulting-driven, top 1%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Lotan experienced with bcg treatment for bladder cancer?
Does Dr. Lotan receive payments from pharmaceutical companies?
How do Dr. Lotan's costs compare to other urology physicians in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology